EU/3/04/259: Orphan designation for the treatment of idiopathic pulmonary fibrosis


Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2009 on request of the sponsor.

On 26 January 2005, orphan designation (EU/3/04/259) was granted by the European Commission to Zambon Group S.p.A, Italy, for acetylcysteine for the treatment of idiopathic pulmonary fibrosis.

Key facts

Active substance
Intended use
Treatment of idiopathic pulmonary fibrosis
Orphan designation status
EU designation number
Date of designation

Zambon S.p.A.
Via Lillo Del Duca 10
20091 Bresso (MI)
Tel: +39 02 66524256

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating